Starpharma 

Starpharma Holdings Limited is an Australian biopharmaceutical company dedicated to advancing and marketing its proprietary dendrimer technology across global pharmaceutical, life-science, and other sectors. Among its current offerings are VivaGel, a non-antibiotic treatment designed for the management and prevention of bacterial vaginosis, alongside the antiviral VivaGel condom and VIRALEZE antiviral nasal spray. Furthermore, the company's extensive pipeline heavily features its DEP dendrimer drug delivery system, which includes several oncology candidates such as DEP docetaxel, DEP cabazitaxel, and DEP irinotecan, all currently undergoing Phase II clinical trials for various cancers. Additional oncology programs encompass DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine. The DEP platform also extends to non-oncology candidates and DEP AZD0466, which is in Phase I/II trials targeting haematological tumors. Established in 1996, Starpharma is headquartered in Abbotsford, Australia.